

a limited exclusion order prohibiting importation of infringing lithium metal oxide cathode materials based upon settlement.

FOR FURTHER INFORMATION CONTACT:

Panyin A. Hughes, Office of the General Counsel, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone 202–205–3042. Copies of non-confidential documents filed in connection with this investigation are or will be available for inspection during official business hours (8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. International Trade Commission, 500 E Street SW., Washington, DC 20436, telephone 202–205–2000. General information concerning the Commission may also be obtained by accessing its Internet server (<https://www.usitc.gov>). The public record for this investigation may be viewed on the Commission's electronic docket (EDIS) at <https://edis.usitc.gov>. Hearing-impaired persons are advised that information on this matter can be obtained by contacting the Commission's TDD terminal on 202–205–1810.

SUPPLEMENTARY INFORMATION: The Commission instituted the underlying investigation on March 30, 2015, based on a complaint filed by BASF Corporation of Florham Park, New Jersey ("BASF") and UChicago Argonne LLC of Lemont, IL ("Argonne") (collectively, "Complainants"). 80 FR 16696 (Mar. 30, 2015). The complaint alleged violations of section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), in the importation into the United States, the sale for importation, and the sale within the United States after importation of certain lithium metal oxide cathode materials, lithium-ion batteries for power tool products containing same, and power tool products with lithium-ion batteries containing same by reason of infringement of one or more of claims 1–4, 7, 13, and 14 of U.S. Patent No. 6,677,082 ("the '082 patent") and claims 1–4, 8, 9, and 17 of U.S. Patent No. 6,680,143 ("the '143 patent"). *Id.* The notice of investigation named the following respondents: Umicore N.V. of Brussels, Belgium; Umicore USA Inc. of Raleigh, North Carolina (collectively, "Umicore"); Makita Corporation of Anjo, Japan; Makita Corporation of America of Buford, Georgia; and Makita U.S.A. Inc. of La Mirada, California (collectively, "Makita"). *Id.* The Office of Unfair Import Investigations was a party to the investigation.

On November 5, 2015, the ALJ granted a joint motion by Complainants and Makita to terminate the

investigation as to Makita based upon settlement. *See* Order No. 32 (Nov. 5, 2015). The Commission determined not to review this order. *See* Notice of Non-Review (Nov. 23, 2015).

On February 29, 2016, the ALJ issued his final initial determination ("ID"), finding a violation of section 337 by Umicore in connection with claims 1–4, 7, 13, and 14 of the '082 patent and claims 1–4, 8, 9, and 17 of the '143 patent. On May 11, 2016, the Commission determined to review the final ID in part. 81 FR 30548–50 (May 17, 2016). The Commission also granted Umicore's request for a Commission hearing. *Id.* On November 17, 2016, the Commission held a hearing on contributory infringement, laches, and the public interest. On review, the Commission determined to affirm the ALJ's finding of violation of section 337 with respect to the claims identified above. 81 FR 93960–62 (Dec. 22, 2016).

Having found a violation of section 337, the Commission determined that the appropriate form of relief was: A limited exclusion order prohibiting the unlicensed entry of lithium metal oxide cathode materials that infringe one or more of claims 1–4, 7, 13, and 14 of the '082 patent, or claims 1–4, 8, 9, and 17 of the '143 patent that are manufactured by, or on behalf of, or imported by or on behalf of Umicore N.V. and Umicore USA Inc. or any of their affiliated companies, parents, subsidiaries, agents, or other related business entities, or their successors or assigns.

On May 5, 2017, BASF, Argonne, and Umicore filed a joint petition under 19 U.S.C. 1337(k) and Commission Rule 210.76(a) (19 CFR 210.76(a)) to rescind the limited exclusion order based upon settlement. The parties filed both confidential and public versions of the settlement agreements. On May 9, 2017, the Commission investigative attorney filed a response in support of the motion.

The Commission has determined to grant the petition. The limited exclusion order issued in this investigation is hereby rescinded.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and in Part 210 of the Commission's Rules of Practice and Procedure (19 CFR 210).

By order of the Commission.

Issued: June 6, 2017.

Lisa R. Barton,

Secretary to the Commission.

[FR Doc. 2017–12035 Filed 6–9–17; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–372]

Exempt Chemical Preparations Under the Controlled Substances Act

AGENCY: Drug Enforcement Administration, Department of Justice.

ACTION: Order with opportunity for comment.

SUMMARY: The applications for exempt chemical preparations received by the Drug Enforcement Administration (DEA) between April 1, 2016, and December 31, 2016, as listed below, were accepted for filing and have been approved or denied as indicated.

DATES: Interested persons may file written comments on this order in accordance with 21 CFR 1308.23(e). Electronic comments must be submitted, and written comments must be postmarked, on or before August 11, 2017. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after 11:59 p.m. Eastern Time on the last day of the comment period.

ADDRESSES: To ensure proper handling of comments, please reference "Docket No. DEA–372" on all correspondence, including any attachments.

- **Electronic comments:** The Drug Enforcement Administration (DEA) encourages that all comments be submitted through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the Web page or to attach a file for lengthier comments. Please go to <http://www.regulations.gov> and follow the online instructions at that site for submitting comments. Upon completion of your submission you will receive a Comment Tracking Number for your comment. Please be aware that submitted comments are not instantaneously available for public view on [Regulations.gov](http://www.Regulations.gov). If you have received a comment tracking number, your comment has been successfully submitted and there is no need to resubmit the same comment.

- **Paper comments:** Paper comments that duplicate the electronic submission are not necessary and are discouraged. Should you wish to mail a comment *in lieu of* an electronic comment, it should be sent via regular or express mail to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DRW, 8701 Morrisette Drive, Springfield, Virginia 22152.

FOR FURTHER INFORMATION CONTACT: Michael J. Lewis, Diversion Control

Division, Drug Enforcement Administration; Mailing Address: 8701 Morrisette Drive, Springfield, Virginia 22152; Telephone: (202) 598-6812.

SUPPLEMENTARY INFORMATION:

Posting of Public Comments

Please note that all comments received are considered part of the public record and made available for public inspection online at <http://www.regulations.gov> and in the DEA's public docket. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter.

If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "PERSONAL IDENTIFYING INFORMATION" in the first paragraph of your comment. You must also place all the personal identifying information you do not want posted online or made available in the public docket in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "CONFIDENTIAL BUSINESS INFORMATION" in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment.

Comments containing personal identifying information and confidential business information identified as directed above will generally be made publicly available in redacted form. If a comment has so much confidential business information that it cannot be effectively redacted, all or part of that comment may not be made publicly available. Comments posted to <http://www.regulations.gov> may include any personal identifying information (such as name, address, and phone number)

included in the text of your electronic submission that is not identified as directed above as confidential.

An electronic copy of this document is available at <http://www.regulations.gov> for easy reference.

Legal Authority

The Drug Enforcement Administration (DEA) implements and enforces titles II and III of the Comprehensive Drug Abuse Prevention and Control Act of 1970, as amended. Titles II and III are referred to as the "Controlled Substances Act" and the "Controlled Substances Import and Export Act," or the "CSA" for the purpose of this action. 21 U.S.C. 801-971. The DEA publishes the implementing regulations for these statutes in title 21 of the Code of Federal Regulations (CFR), chapter II.

The CSA and its implementing regulations are designed to prevent, detect, and eliminate the diversion of controlled substances and listed chemicals into the illicit market while ensuring an adequate supply is available for the legitimate medical, scientific, research, and industrial needs of the United States. Controlled substances have the potential for abuse and dependence and are controlled to protect the public health and safety.

Section 201 of the CSA (21 U.S.C. 811) authorizes the Attorney General, by regulation, to exempt from certain provisions of the CSA certain compounds, mixtures, or preparations containing a controlled substance, if he finds that such compounds, mixtures, or preparations meet the requirements detailed in 21 U.S.C. 811(g)(3)(B).¹ The DEA regulations at 21 CFR 1308.23 and 1308.24 further detail the criteria by which the DEA Assistant Administrator may exempt a chemical preparation or mixture from certain provisions of the CSA. The Assistant Administrator may, pursuant to 21 CFR 1308.23(f), modify or revoke the criteria by which exemptions are granted and modify the scope of exemptions at any time.

Exempt Chemical Preparation Applications Submitted Between April 1, 2016, and December 31, 2016

The Assistant Administrator received applications between April 1, 2016, and December 31, 2016, requesting exempt chemical preparation status detailed in 21 CFR 1308.23. Pursuant to the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23, the Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart I below is intended for laboratory, industrial, educational, or special research purposes and not for general administration to a human being or animal and either: (1) Contains no narcotic controlled substance and is packaged in such a form or concentration that the packaged quantity does not present any significant potential for abuse; or (2) contains either a narcotic or non-narcotic controlled substance and one or more adulterating or denaturing agents in such a manner, combination, quantity, proportion, or concentration that the preparation or mixture does not present any potential for abuse; if the preparation or mixture contains a narcotic controlled substance, it must be formulated in such a manner that it incorporates methods of denaturing or other means so that the preparation or mixture is not liable to be abused or have ill effects if abused, and so that the narcotic substance cannot in practice be removed.

Accordingly, pursuant to 21 U.S.C. 811(g)(3)(B), 21 CFR 1308.23, and 21 CFR 1308.24, the Assistant Administrator has determined that each of the chemical preparations or mixtures generally described in Chart I below and specifically described in the application materials received by the DEA, is exempt, to the extent described in 21 CFR 1308.24, from application of sections 302, 303, 305, 306, 307, 308, 309, 1002, 1003, and 1004 (21 U.S.C. 822-823, 825-829, and 952-954) of the CSA, and 21 CFR 1301.74, as of the date that was provided in the approval letters to the individual requesters.

CHART I

Supplier	Product name	Form	Application date
Aalto Scientific, Ltd	Endocrine Program	Amber vial: 5 mL	8/23/2016
Aalto Scientific, Ltd	Endocrinology	Amber vial: 5 mL	8/23/2016
Aalto Scientific, Ltd	Linearity FD Testosterone, Siemens Centaur	Kit: 5 vials; 3 mL each	12/7/2016
Absolute Standards, Inc	ISO G34 Calibrator Spike High	Glass ampoule: 1 mL	8/3/2016
Absolute Standards, Inc	ISO G34 Calibrator Spike Low	Glass ampoule: 1 mL	8/3/2016
Absolute Standards, Inc	ISO G34 Calibrator Spike Solution	Glass ampoule: 1 mL	8/3/2016

¹ This authority has been delegated from the Attorney General to the Administrator of the DEA

by 28 CFR 0.100, and subsequently redelegated to

the Deputy Assistant Administrator pursuant to Section 7 of 28 CFR 0.104, Appendix to Subpart R.

CHART I—Continued

Supplier	Product name	Form	Application date
Absolute Standards, Inc	ISO G34 Internal Standard	Glass ampoule: 1 mL	8/3/2016
Accriva Diagnostics, Inc	Hemochron PT	Box: 45 cuvettes; 7.5µL each.	5/17/2016
Arbor Assays	Testosterone 5-pack Enzyme Immunoassay Kit (K032–H5)	Kit: 400 µL vial	10/18/2016
Arbor Assays	Testosterone Enzyme Immunoassay Kit (ISWE001)	Kit: 1 mL vial	10/18/2016
Arbor Assays	Testosterone Enzyme Immunoassay Kit (K032–H1)	Kit: 90 µL vial	10/18/2016
Arbor Assays	Testosterone Standard (1,000 ng/mL)	Plastic vial: 1 mL	10/18/2016
Arbor Assays	Testosterone Standard (200,000 pg/mL)	Plastic vial: 90 µL	10/18/2016
Arbor Assays	Testosterone Standard (200,000 pg/mL)	Plastic vial: 400 µL	10/18/2016
Biochemical Diagnostics, Inc	Detectabuse Custom Liquid Control Urine, MC252	Glass vial: 1 mL–200 mL	7/29/2016
Biochemical Diagnostics, Inc	Detectabuse Custom Liquid Control Urine, MC253	Glass vials: 1 mL–200 mL	9/30/2016
Biochemical Diagnostics, Inc	Detectabuse Custom Liquid Control Urine, MC254	Glass vial: 1 mL–200 mL	7/29/2016
Biochemical Diagnostics, Inc	Detectabuse Custom Liquid Control Urine, MC255	Glass vial: 1 mL–200 mL	7/29/2016
Biochemical Diagnostics, Inc	Detectabuse Custom Liquid Control Urine, MC256	Glass vials: 1 mL–200 mL	12/19/2016
Biochemical Diagnostics, Inc	Detectabuse Custom Liquid Control Urine, MC257	Glass vials: 1 mL–200 mL	12/19/2016
Cayman Chemical Company	11-Keto Testosterone CRM; 1 mg/mL in Acetonitrile	Glass ampule: 1 mL	6/28/2016
Cayman Chemical Company	AB-CHMINACA (CRM); 1 mg/mL in Acetonitrile	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	AB-CHMINACA (CRM); 1 mg/mL in Methanol	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	AB-CHMINACA (CRM); 100 µg/mL in Acetonitrile	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	AB-CHMINACA (CRM); 100 µg/mL in Methanol	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	AB-PINACA CRM; 1 mg/mL in Methanol	Glass ampule: 1 mL	6/28/2016
Cayman Chemical Company	Acetyl Fentanyl CRM; 1 mg/mL in Methanol	Glass ampule: 1 mL	6/28/2016
Cayman Chemical Company	Acetyl Fentanyl CRM; 100 µg/mL in Methanol	Glass ampule: 1 mL	6/28/2016
Cayman Chemical Company	Cocaine CRM; 1 mg/mL in Acetonitrile	Glass ampule: 1 mL	6/28/2016
Cayman Chemical Company	Cocaine/Heroin/Methamphetamine Mixture CRM; 1 mg/mL each in Acetonitrile.	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	Cocaine/Heroin/Methamphetamine Mixture CRM; 100 µg/mL each in Acetonitrile.	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	Cocaine/Heroin/Methamphetamine Mixture CRM; 250 µg/mL each in Acetonitrile.	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	Cocaine/Heroin/Methamphetamine Mixture CRM; 500 µg/mL each in Acetonitrile.	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	GC-MS Drug Standard Mixture 1 in Acetonitrile	Glass ampule: 1 mL	6/28/2016
Cayman Chemical Company	Phytocannabinoid Mixture 1; 1 mg/mL in Acetonitrile	Glass ampule: 1 mL	6/28/2016
Cayman Chemical Company	Tapentadol (hydrochloride) CRM; 1 mg/mL in Acetonitrile	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	Tapentadol (hydrochloride) CRM; 1 mg/mL in Methanol	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	Tapentadol (hydrochloride) CRM; 100 µg/mL in Acetonitrile	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	Tapentadol (hydrochloride) CRM; 100 µg/mL in Methanol	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	THJ2201 (CRM); 1 mg/mL in Acetonitrile	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	THJ2201 (CRM); 1 mg/mL in Methanol	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	THJ2201 (CRM); 100 µg/mL in Acetonitrile	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	THJ2201 (CRM); 100 µg/mL in Methanol	Glass ampule: 1 mL	8/26/2016
Cayman Chemical Company	ToxBox THC/THC Metabolite Plate	48-well plate	6/28/2016
Cerilliant Corporation	(±)-11-Hydroxy-delta9-THC glucuronide (0.01 mg/mL)	Glass ampule: 1 mL	11/11/2016
Cerilliant Corporation	(±)-Cannabicyclol (1.0 mg/mL)	Glass ampule: 1.0 mL	7/18/2016
Cerilliant Corporation	(±)-cis-3-Methylfentanyl HCl (0.05 mg/mL)	Glass ampule: 1 mL	6/21/2016
Cerilliant Corporation	(±)-cis-3-Methylfentanyl HCl (0.1 mg/mL)	Glass ampule: 0.5 mL	7/18/2016
Cerilliant Corporation	5alpha-Dihydrotestosterone-D3 [16, 16, 17–D3]; 10 µg/mL	Glass ampule: 1 mL	9/28/2016
Cerilliant Corporation	6beta-Naltrexol (1 mg/mL)	Glass ampule: 1 mL	5/6/2016
Cerilliant Corporation	AH-7921 HCl (1 mg/mL)	Glass ampule: 1 mL	5/20/2016
Cerilliant Corporation	AH-7921-D3 HCl (0.1 mg/mL)	Glass ampule: 1 mL	5/20/2016
Cerilliant Corporation	Brivaracetam-D3 (0.1 mg/mL)	Glass ampule: 1 mL	11/30/2016
Cerilliant Corporation	Butyryl fentanyl (0.05 mg/mL)	Glass ampule: 1 mL	6/21/2016
Cerilliant Corporation	Butyryl fentanyl (0.1 mg/mL)	Glass ampule: 0.5 mL	7/18/2016
Cerilliant Corporation	Cannabichromenic acid (CBCA) (1.0 mg/mL)	Glass ampule: 1 mL	11/30/2016
Cerilliant Corporation	Cannabicyclol acid (CBLA) (1.0 mg/mL)	Glass ampule: 1 mL	11/30/2016
Cerilliant Corporation	Carfentanil (0.1 mg/mL)	Glass ampule: 0.5 mL	9/28/2016
Cerilliant Corporation	Carfentanil oxalate (0.1 mg/mL)	Glass ampule: 0.5 mL	11/30/2016
Cerilliant Corporation	Carfentanil-D5 oxalate (0.1 mg/mL)	Glass ampule: 0.5 mL	11/30/2016
Cerilliant Corporation	Clorazepate dipotassium (1 mg/mL)	Glass ampule: 1 mL	5/6/2016
Cerilliant Corporation	Dihydrotestosterone Calibrator Level 1 (20 pg/mL)	Cryovial: 1 mL	8/12/2016
Cerilliant Corporation	Dihydrotestosterone Calibrator Level 2 (50 pg/mL)	Cryovial: 1 mL	8/12/2016
Cerilliant Corporation	Dihydrotestosterone Calibrator Level 3 (100 pg/mL)	Cryovial: 1 mL	8/12/2016
Cerilliant Corporation	Dihydrotestosterone Calibrator Level 4 (500 pg/mL)	Cryovial: 1 mL	8/12/2016
Cerilliant Corporation	Dihydrotestosterone Calibrator Level 5 (1000 pg/mL)	Cryovial: 1 mL	8/12/2016
Cerilliant Corporation	Dihydrotestosterone Calibrator Level 6 (2500 pg/mL)	Cryovial: 1 mL	8/12/2016
Cerilliant Corporation	Dihydrotestosterone Calibrator Level 7 (10 ng/mL)	Cryovial: 1 mL	8/12/2016
Cerilliant Corporation	Diphenoxylate HCl (1 mg/mL)	Glass ampule: 1 mL	5/20/2016
Cerilliant Corporation	Furanyl fentanyl (0.1 mg/mL)	Glass ampule: 0.5 mL	11/30/2016
Cerilliant Corporation	Norhydromorphone-D3 HCl (0.1 mg/mL)	Glass ampule: 1.0 mL	7/18/2016
Cerilliant Corporation	Noroxymorphone-D3 HCl (0.1 mg/mL)	Glass ampule: 1.0 mL	7/18/2016

CHART I—Continued

Supplier	Product name	Form	Application date
Cerilliant Corporation	Pholcodine (1 mg/mL)	Glass ampule: 1 mL	5/6/2016
Cerilliant Corporation	Tapentadol-D3 HCl (1 mg/mL)	Glass ampule: 1 mL	11/11/2016
Cerilliant Corporation	U-47700 (1.0 mg/mL)	Glass ampule: 1 mL	11/30/2016
IDEXX Laboratories	Coag Dx PT	Box: 10 cartridges; 7.5µL each.	10/21/2016
IDEXX Laboratories	Coag Dx PT Cartridge	Cartridges: 7.5µL each	10/21/2016
Immunalysis Corporation	cTHC Urine Calibrator 1 (20 ng/mL)	Dropper bottle: 5 mL, 15 mL.	5/27/2016
Immunalysis Corporation	cTHC Urine Calibrator 2 (50 ng/mL)	Dropper bottle: 5 mL, 15 mL.	5/27/2016
Immunalysis Corporation	cTHC Urine Calibrator 3 (100 ng/mL)	Dropper bottle: 5 mL, 15 mL.	5/27/2016
Immunalysis Corporation	cTHC Urine Calibrator 4 (200 ng/mL)	Dropper bottle: 5 mL, 15 mL.	5/27/2016
Immunalysis Corporation	cTHC Urine Control HIGH (62.5 ng/mL)	Dropper bottle: 5 mL, 15 mL.	5/27/2016
Immunalysis Corporation	cTHC Urine Control LOW (37.5 ng/mL)	Dropper bottle: 5 mL, 15 mL.	5/27/2016
Immunalysis Corporation	Fentanyl Urine Calibrator 1 (1 ng/mL)	Dropper bottle: 5 mL	5/27/2016
Immunalysis Corporation	Fentanyl Urine Calibrator 2 (2 ng/mL)	Dropper bottle: 5 mL	5/27/2016
Immunalysis Corporation	Fentanyl Urine Calibrator 3 (4 ng/mL)	Dropper bottle: 5 mL	5/27/2016
Immunalysis Corporation	Fentanyl Urine Control HIGH (1.5 ng/mL)	Dropper bottle: 5 mL	5/27/2016
Immunalysis Corporation	Fentanyl Urine Control LOW (0.5 ng/mL)	Dropper bottle: 5 mL	5/27/2016
Immunalysis Corporation	MDC Calibrator 1	Dropper bottle: 15 mL, 25 mL.	5/27/2016
Immunalysis Corporation	MDC Calibrator 2	Dropper bottle: 15 mL, 25 mL.	5/27/2016
Immunalysis Corporation	MDC Calibrator 3	Dropper bottle: 15 mL, 25 mL.	5/27/2016
Immunalysis Corporation	MDC Calibrator 4	Dropper bottle: 15 mL, 25 mL.	5/27/2016
Immunalysis Corporation	MDC Control HIGH Set 1	Dropper bottle: 15 mL, 25 mL.	5/27/2016
Immunalysis Corporation	MDC Control HIGH Set 1	Dropper bottle: 15 mL, 25 mL.	5/27/2016
Immunalysis Corporation	MDC Control LOW Set 1	Dropper bottle: 15 mL, 25 mL.	5/27/2016
Immunalysis Corporation	MDC Control LOW Set 2	Dropper bottle: 15 mL, 25 mL.	5/27/2016
Immunalysis Corporation	Opiates Urine Calibrator 2000 1 (1000 ng/mL)	Dropper bottle: 5 mL, 15 mL.	5/27/2016
Immunalysis Corporation	Opiates Urine Calibrator 2000 2 (2000 ng/mL)	Dropper bottle: 5 mL, 15 mL.	5/27/2016
Immunalysis Corporation	Opiates Urine Calibrator 2000 3 (4000 ng/mL)	Dropper bottle: 5 mL, 15 mL.	5/27/2016
Immunalysis Corporation	Opiates Urine Calibrator 2000 4 (6000 ng/mL)	Dropper bottle: 5 mL, 15 mL.	5/27/2016
Immunalysis Corporation	Oxazepam Urine Control HIGH (125 ng/mL)	Dropper bottle: 5 mL, 15 mL.	5/27/2016
Immunalysis Corporation	Oxazepam Urine Control LOW (75 ng/mL)	Dropper bottle: 5 mL, 15 mL.	5/27/2016
Instrumentation Laboratory	Gem Test PT	Box: 45 cuvettes; 7.5µL each.	10/6/2016
IsoSciences, LLC	Codeine-[13C4, 15N], 1000 µg/mL in methanol	Amber ampule: 1 mL	10/20/2016
IsoSciences, LLC	Codeine-6β-Glucuronide-[13C10, 15N], 1000 µg/mL in methanol:water (2:8).	Amber ampule: 1 mL	10/20/2016
IsoSciences, LLC	Morphine-[13C4, 15N], 1000 µg/mL in methanol	Amber ampule: 1 mL	10/20/2016
IsoSciences, LLC	Morphine-6β-Glucuronide-[13C10, 15N], 1000 µg/mL in methanol:water (2:8).	Amber ampule: 1 mL	10/20/2016
IsoSciences, LLC	Testosterone-[2H8], 100 µg/mL in methanol	Amber Ampule: 1 mL	8/10/2016
IsoSciences, LLC	Testosterone-[2H8], 1000 µg/mL in methanol	Amber Ampule: 1 mL	8/10/2016
ITC	Hemochron Jr	Box: 45 cuvettes; 7.5µL each.	7/1/2016
Lipomed Inc	25B-NB2OMe (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	25C-NB2OMe (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	25I-NB2OMe (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	25I-NB2OMe-D9 (0.1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	25I-NB2OMe-D9 (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	3,4-Methylenedioxypyrovalerone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	3,4-Methylenedioxy-α-pyrrolidinopropiophenone (1 mg/mL methanol).	Glass ampule: 1 mL	10/28/2016

CHART I—Continued

Supplier	Product name	Form	Application date
Lipomed Inc	3-Desmethylprodine (1 mg/mL acetonitrile)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	4-Ethylmethcathinone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	4-Methylethcathinone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	4-Methylmethcathinone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	4-Methylmethcathinone-D3 (0.1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	4-Methylmethcathinone-D3 (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Benzodiazepines mixture (.001 mg free base/mL acetonitrile)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Benzodiazepines mixture 5 (1 mg free base/mL acetonitrile)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Bufotenine.oxalate.monohydrate (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Butabarbital (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Butalbital (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Butalbital-D5 (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Butylone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Cannabidiol-D3 (0.1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Cannabidiol-D3 (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Cannabinol-D3 (0.1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Cannabinol-D3 (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Carisoprodol (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Clotiazepam (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Cocaethylene-D3 (1 mg/mL acetonitrile)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Cocaine mixture 2 (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Desomorphine (1 mg/mL acetonitrile)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Ethylone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	JWH-018 (0.1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	JWH-018 (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	JWH-018-D11 metabolite (0.1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	JWH-018-D11 metabolite (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	JWH-019 (0.1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	JWH-019 (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	JWH-081 (0.1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	JWH-081 (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	JWH-122 (0.1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	JWH-122 (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	JWH-200 (0.1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	JWH-200 (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	L-Methamphetamine (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Loprazolam (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Mazindol (1 mg/mL Dimethylformamide)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Meprobamate (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Methandienone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Methylone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Methylone-D3 (0.1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Methylone-D3 (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	N,N-Dimethylamphetamine (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Naphyrone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Nimetazepam (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Norbuprenorphine (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Normeperidine (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Pentedrone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Pentylone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Phenobarbital-D5 (side chain) (0.1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Phenobarbital-D5 (side chain) (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Pregabalin (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Propoxyphen-D5 (0.1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Propoxyphen-D5 (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Pyrovalerone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	α -Pyrrolidinopropiophenone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	α -Pyrrolidinovaleophenone (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Microgenics Corporation	Cascadian SM Total Testosterone Internal Standard	Box: 8 bottles, 29 mL each.	12/16/2016
Microgenics Corporation	Cedia Buprenorphine OFT Control Set (Low and High) Catalog Number: 10022377.	Vial: 10 mL; Box: 2 vials ..	11/15/2016
Microgenics Corporation	Cedia Buprenorphine OFT Cutoff Calibrator Catalog Number: 10022376.	Vial: 5 mL; Box: 1 vial	11/15/2016
Microgenics Corporation	Cedia Multi-Drug OFT Cutoff Calibrator Set B Catalog Number: 10022355.	Vial: 10 mL; Box: 1 vial ...	10/20/2016
Microgenics Corporation	Cedia Multi-Drug OFT Cutoff Control Set B (Low and High) Catalog Number: 10022356.	Vial: 15 mL; Box: 2 vials ..	10/20/2016
Microgenics Corporation	Intercept i2he Multi-Drug Oral Fluid Cutoff Calibrator Set B Catalog Number: 1001-0419.	Vial: 10 mL; Box: 1 vial ...	10/19/2016
Microgenics Corporation	Intercept i2he Multi-Drug Oral Fluid Cutoff Control Set B (Low and High) Catalog Number: 1001-0420.	Vial: 15 mL; Box: 2 vials ..	10/19/2016

CHART I—Continued

Supplier	Product name	Form	Application date
Microgenics Corporation	Thermo Scientific CEDIA Buprenorphine II Calibrator 10 ng/mL Catalog Number: 10020799.	Vial: 5 mL Box: 1 vial	8/30/2016
Microgenics Corporation	Thermo Scientific CEDIA Buprenorphine II Calibrator 100 ng/mL Catalog Number: 10020802.	Vial: 5 mL Box: 1 vial	8/30/2016
Microgenics Corporation	Thermo Scientific CEDIA Buprenorphine II Calibrator 20 ng/mL Catalog Number: 10020800.	Vial: 5 mL Box: 1 vial	8/30/2016
Microgenics Corporation	Thermo Scientific CEDIA Buprenorphine II Calibrator 50 ng/mL Catalog Number: 10020801.	Vial: 5 mL Box: 1 vial	8/30/2016
Microgenics Corporation	Thermo Scientific CEDIA Buprenorphine II Controls (Low and High) Catalog Number: 10020804.	Vial: 5 mL Box: 4 vials	8/30/2016
Siemens Healthcare Diagnostics, Inc.	BK Emit II Plus Oxycodone Negative Control 100	Bulk Container: 1 L–50 L	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Emit II Plus Oxycodone Negative Control 100	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Emit II Plus Oxycodone Negative Control 300	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Emit II Plus Oxycodone Positive Control 100	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Emit II Plus Oxycodone Positive Control 300	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Emit II Plus Specialty Multi Drug Calibrator/Control Level 1	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Emit II Plus Specialty Multi Drug Calibrator/Control Level 2	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Emit II Plus Specialty Multi Drug Calibrator/Control Level 3	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Emit II Plus Specialty Multi Drug Calibrator/Control Level 4	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	FC Emit II Plus Oxycodone Negative Control 100	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	FC Emit II Plus Oxycodone Negative Control 300	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	FC Emit II Plus Oxycodone Positive Control 100	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	FC Emit II Plus Oxycodone Positive Control 300	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	FC Emit II Plus Specialty Multi Drug Calibrator/Control Level 1	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	FC Emit II Plus Specialty Multi Drug Calibrator/Control Level 2	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	FC Emit II Plus Specialty Multi Drug Calibrator/Control Level 3	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	FC Emit II Plus Specialty Multi Drug Calibrator/Control Level 4	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	MP FC Emit Oxycodone Negative Control 100	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	MP FC Emit Oxycodone Negative Control 300	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	MP FC Emit Oxycodone Positive Control 100	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	MP FC Emit Oxycodone Positive Control 300	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	MP FC Emit Specialty Multi Drug Calibrator/Control LVL 1	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	MP FC Emit Specialty Multi Drug Calibrator/Control LVL 2	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	MP FC Emit Specialty Multi Drug Calibrator/Control LVL 3	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	MP FC Emit Specialty Multi Drug Calibrator/Control LVL 4	Vial: 10 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Pilot Emit II Plus Oxycodone Negative Control 100	Pilot container: 4 mL–200 mL.	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Pilot Emit II Plus Oxycodone Negative Control 300	Pilot container: 4 mL–200 mL.	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Pilot Emit II Plus Oxycodone Positive Control 100	Pilot container: 4 mL–200 mL.	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Pilot Emit II Plus Oxycodone Positive Control 300	Pilot container: 4 mL–200 mL.	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Pilot Emit II Plus Specialty Multi Drug Calibrator/Control LVL 1	Pilot container: 4 mL–200 mL.	8/23/2016

CHART I—Continued

Supplier	Product name	Form	Application date
Siemens Healthcare Diagnostics, Inc.	Pilot Emit II Plus Specialty Multi Drug Calibrator/Control LVL 2 ...	Pilot container: 4 mL–200 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Pilot Emit II Plus Specialty Multi Drug Calibrator/Control LVL 3 ...	Pilot container: 4 mL–200 mL	8/23/2016
Siemens Healthcare Diagnostics, Inc.	Pilot Emit II Plus Specialty Multi Drug Calibrator/Control LVL 4 ...	Pilot container: 4 mL–200 mL	8/23/2016
USP	USP Levomethorphan Solution Reference Standard	Box: 3 vials, 1.2 mL each	9/13/2016
UTAK Laboratories, Inc	AED II HR Serum Control, Ref: 72740	Carton: 5 bottles, 5 mL each.	12/27/2016
UTAK Laboratories, Inc	AED II MR Serum Control, Ref: 72741	Carton: 5 bottles, 5 mL each.	12/27/2016
UTAK Laboratories, Inc	Benzodiazepines 2 Serum Control HR, Ref: 22615	Carton: 5 bottles, 5 mL each.	12/27/2016
UTAK Laboratories, Inc	Benzodiazepines 2 Serum Control MR, Ref: 22616	Carton: 5 bottles, 5 mL each.	12/27/2016
UTAK Laboratories, Inc	Benzodiazepines Plus 100 Urine Control, Ref: 12090	Carton: 5 bottles, 5 mL each.	12/27/2016
UTAK Laboratories, Inc	Benzodiazepines Plus 100 Whole Blood Control, Ref: 12092	Carton: 5 bottles, 5 mL each.	12/27/2016
UTAK Laboratories, Inc	Benzodiazepines Plus 400 ng/mL Urine Control, Ref: 12091	Carton: 5 bottles, 5 mL each.	12/27/2016
UTAK Laboratories, Inc	Clonazepam Serum Control HR, Ref: 22610	Carton: 5 bottles, 5 mL each.	12/27/2016
UTAK Laboratories, Inc	Clonazepam Serum Control MR, Ref: 22611	Carton: 5 bottles, 5 mL each.	12/27/2016
UTAK Laboratories, Inc	DHEA Plus High Serum Control, Ref: 51411	Carton: 5 bottles, 3 mL each.	12/27/2016
UTAK Laboratories, Inc	DHEA Plus Low Serum Control, Ref: 51410	Carton: 5 bottles, 3 mL each.	12/27/2016
UTAK Laboratories, Inc	Pentobarbital Serum Control, Ref: 66319	Carton: 5 bottles, 5 mL each.	12/27/2016
UTAK Laboratories, Inc	Steroids Level 1 SMx Serum Control, Ref: 51401	Carton: 5 bottles, 3 mL each.	12/27/2016
UTAK Laboratories, Inc	Steroids Level 2 SMx Serum Control, Ref: 51402	Carton: 5 bottles, 3 mL each.	12/27/2016
UTAK Laboratories, Inc	Steroids Level 3 SMx Serum Control, Ref: 51403	Carton: 5 bottles, 3 mL each.	12/27/2016
UTAK Laboratories, Inc	Steroids Level 4 SMx Serum Control, Ref: 51404	Carton: 5 bottles, 3 mL each.	12/27/2016

The Assistant Administrator has found that each of the compounds, mixtures, and preparations described in Chart II below is not consistent with the criteria stated in 21 U.S.C. 811(g)(3)(B) and in 21 CFR 1308.23. Accordingly, the

Assistant Administrator has determined that the chemical preparations or mixtures generally described in Chart II below and specifically described in the application materials received by DEA, are not exempt from application of any

part of the CSA or from application of any part of the CFR, with regard to the requested exemption pursuant to 21 CFR 1308.23, as of the date that was provided in the determination letters to the individual requesters.

CHART II

Supplier	Product name	Form	Application date
Aalto Scientific, Ltd	General Chemistry Serum	Box: 1056 vials; 5 mL each	6/20/2016
Biochemical Diagnostics, Inc	Detectabuse Custom Liquid Control Urine, MC253	Glass vial: 1 mL–200 mL	7/29/2016
Cerilliant Corporation	(±)-cis-3-Methylfentanyl HCl (0.1 mg/mL)	Glass ampule: 1 mL	6/21/2016
Cerilliant Corporation	(±)-cis-3-Methylfentanyl HCl (1 mg/mL)	Glass ampule: 1 mL	5/6/2016
Cerilliant Corporation	Butyryl fentanyl (0.1 mg/mL)	Glass ampule: 1 mL	6/21/2016
Cerilliant Corporation	Butyryl fentanyl HCl (1 mg/mL)	Glass ampule: 1 mL	5/20/2016
Lipomed Inc	Benzodiazepines mixture 8 (0.25 mg free base/mL acetonitrile)	Glass ampule: 1 mL	10/28/2016
Lipomed Inc	Estazolam (1 mg/mL methanol)	Glass ampule: 1 mL	10/28/2016
Siemens Healthcare Diagnostics, Inc	BK Emit II Plus Oxycodone Negative Control 300	Bulk Container: 1 L–50 L	8/23/2016
Siemens Healthcare Diagnostics, Inc	BK Emit II Plus Oxycodone Positive Control 100	Bulk Container: 1 L–50 L	8/23/2016
Siemens Healthcare Diagnostics, Inc	BK Emit II Plus Oxycodone Positive Control 300	Bulk Container: 1 L–50 L	8/23/2016
Siemens Healthcare Diagnostics, Inc	BK Emit II Plus Specialty Multi Drug Calibrator/Control LVL 1	Bulk Container: 1 L–50 L	8/23/2016
Siemens Healthcare Diagnostics, Inc	BK Emit II Plus Specialty Multi Drug Calibrator/Control LVL 2	Bulk Container: 1 L–50 L	8/23/2016
Siemens Healthcare Diagnostics, Inc	BK Emit II Plus Specialty Multi Drug Calibrator/Control LVL 3	Bulk Container: 1 L–50 L	8/23/2016
Siemens Healthcare Diagnostics, Inc	BK Emit II Plus Specialty Multi Drug Calibrator/Control LVL 4	Bulk Container: 1 L–50 L	8/23/2016

Scope of Approval

The exemptions are applicable only to the precise preparation or mixture described in the application submitted to DEA in the form(s) listed in this order and only for those sections of the CSA and the CFR that are specifically identified. In accordance with 21 CFR 1308.24(h), any change in the quantitative or qualitative composition of the preparation or mixture, or change in the trade name or other designation of the preparation or mixture after the date of application requires a new application. In accordance with 21 CFR 1308.24(g), the DEA may prescribe requirements other than those set forth in 1308.24(b)–(e) on a case-by-case basis for materials exempted in bulk quantities. Accordingly, in order to limit opportunity for diversion from the larger bulk quantities, the DEA has determined that each of the exempted bulk products listed in this order may only be used in-house by the manufacturer, and may not be distributed for any purpose, or transported to other facilities.

Additional exempt chemical preparation requests received between April 1, 2016, and December 31, 2016, and not otherwise referenced in this order may remain under consideration until the DEA receives additional information required, pursuant to 21 CFR 1308.23(d), as detailed in separate correspondence to individual requesters. The DEA's order on such requests will be communicated to the public in a future **Federal Register** publication.

The DEA also notes that these exemptions are limited to exemption from only those sections of the CSA and the CFR that are specifically identified in 21 CFR 1308.24(a). All other requirements of the CSA and the CFR apply, including registration as an importer as required by 21 U.S.C. 957.

Opportunity for Comment

Pursuant to 21 CFR 1308.23, any interested person may submit written comments on or objections to any chemical preparation in this order that has been approved or denied as exempt. If any comments or objections raise significant issues regarding any finding of fact or conclusion of law upon which this order is based, the Assistant Administrator will immediately suspend the effectiveness of any applicable part of this order until he may reconsider the application in light of the comments and objections filed.

Approved Exempt Chemical Preparations Are Posted on DEA's Web Site

A list of all current exemptions, including those listed in this order, is available on the DEA's Web site at http://www.DEAdiversion.usdoj.gov/schedules/exempt/exempt_chemlist.pdf. The dates of applications of all current exemptions are posted for easy reference.

Dated: May 24, 2017.

Louis J. Milione,
Assistant Administrator.

[FR Doc. 2017–12110 Filed 6–9–17; 8:45 am]

BILLING CODE 4410–09–P

DEPARTMENT OF LABOR

Mine Safety and Health Administration

[OMB Control No. 1219–0NEW]

Proposed Extension of Information Collection; Performance Reports for MSHA Grants

AGENCY: Mine Safety and Health Administration, Labor.

ACTION: Request for public comments.

SUMMARY: The Department of Labor, as part of its continuing effort to reduce paperwork and respondent burden, conducts a pre-clearance consultation program to provide the general public and Federal agencies with an opportunity to comment on proposed collections of information in accordance with the Paperwork Reduction Act of 1995, 44 U.S.C. 3506(c)(2)(A). This program helps to assure that requested data can be provided in the desired format, reporting burden (time and financial resources) is minimized, collection instruments are clearly understood, and the impact of collection requirements on respondents can be properly assessed. Currently, the Mine Safety and Health Administration (MSHA) is soliciting comments on the information collection for Performance Reports for MSHA Grants.

DATES: All comments must be received on or before August 11, 2017.

ADDRESSES: Comments concerning the information collection requirements of this notice may be sent by any of the methods listed below.

- **Federal E-Rulemaking Portal:** <http://www.regulations.gov>. Follow the on-line instructions for submitting comments for docket number MSHA–2017–0007.

- **Regular Mail:** Send comments to USDOL—MSHA, Office of Standards, Regulations, and Variances, 201 12th

Street South, Suite 4E401, Arlington, VA 22202–5452.

- **Hand Delivery:** USDOL—Mine Safety and Health Administration, 201 12th Street South, Suite 4E401, Arlington, VA 22202–5452. Sign in at the receptionist's desk on the 4th floor via the East elevator.

FOR FURTHER INFORMATION CONTACT: Sheila McConnell, Director, Office of Standards, Regulations, and Variances, MSHA, at MSHA.information.collections@dol.gov (email); 202–693–9440 (voice); or 202–693–9441 (facsimile).

SUPPLEMENTARY INFORMATION:

I. Background

Section 103(h) of the Federal Mine Safety and Health Act of 1977 (Mine Act), 30 U.S.C. 813(h), authorizes MSHA to collect information necessary to carry out its duty in protecting the safety and health of miners. Further, Sec. 101(a) of the Mine Act, 30 U.S.C. 811 authorizes the Secretary of Labor to develop, promulgate, and revise as may be appropriate, improved mandatory health or safety standards for the protection of life and prevention of injuries in coal and metal and nonmetal mines.

MSHA is requesting approval of a new information collection for narrative reporting of grant requirements. One of MSHA's strategic goals is to “improve workplace safety and health” through the strategic objective “secure safe and healthy workplaces, particularly in high-risk industries.” MSHA's goal in accomplishing this objective is to “prevent death, disease, and injury from mining and promote safe and healthful workplaces for the Nation's miners.” Sec. 115 of the Mine Act, as amended, requires mine operators to have a health and safety training program. Under Sec. 503 of the Mine Act, as amended, the Secretary may award grants to States to assist in developing and enforcing State mining laws and regulations, to improve State workers' compensation and mining occupational disease laws and programs, and to improve safety and health conditions in the Nation's mines through Federal-State coordination and cooperation.

Therefore, MSHA seeks the Office of Management and Budget's (OMB) clearance of the information collections the Department of Labor (DOL) requires to carry out its grant program through MSHA. This information collection covers the performance reporting for MSHA for Narrative Reports. MSHA is seeking to transfer its DOL-approved burden on the Narrative Reports under OMB No. 1225–0086 to an MSHA information collection.